Antibody production from hybrid cell line
AssigneeNational Research Development Corporation
InventorsGiovanni Galfre, Cesar Milstein, Bruce W. Wright
Life of this patent
Estimating the term…
Abstract
Hybrid cell lines for providing antibodies are produced from a rat myeloma cell line having the C.N.C.M. designation I-078. In production of the hybrid cells, the rat myeloma cell line is fused with immunocyte cells such as spleen cells from an animal such as a rat sensitized to an immunogen. Use of the rat myeloma cell line is particularly advantageous for in vivo cultivation of a hybrid cell line to produce antibodies.
Claims15
A substantially pure rat myeloma cell line having the C.N.C.M. designation I-078.
A hybrid cell line prepared from cells of the cell line C.N.C.M. I-078 through the fusion thereof with immunocyte cells from an animal sensitized to an immunogen in a nutrient medium for said cells, followed by isolation of the hybrid cell line from the resultant mixture of cells.
An in vitro cell culture system comprising a substantially pure rat myeloma cell line designated C.N.C.M. I-078 in a nutrient medium therefor.
A cell fusion system which comprises cells of the cell line C.N.C.M. I-078 and immunocyte cells from an animal sensitized to an immunogen in a nutrient culture medium therefor together with an agent which promotes the fusion of said cells.
Dependencies are inferred from the claim text.